Market Cap 4.71B
Revenue (ttm) 0.00
Net Income (ttm) -413.84M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,077,800
Avg Vol 1,843,556
Day's Range N/A - N/A
Shares Out 175.28M
Stochastic %K 28%
Beta 0.56
Analysts Strong Sell
Price Target $39.27

Company Profile

Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in New York, New...

Industry: Biotechnology
Sector: Healthcare
Phone: 917 580 3099
Address:
320 West 37th Street, 6th Floor, New York, United States
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 25 at 3:21 PM
Actionable Trade Alert for $IMVT: Market Context: $IMVT is currently trading at $26.88, showing strong momentum with an RSI of 72.23, indicating overbought conditions. The stock is above its 30-day MA of 24.31 and 50-day MA of 23.13, suggesting bullish sentiment. The 60-day high of $27.69 indicates potential resistance, while the low of $15.95 provides a solid support level. Directional Bias: The strong RSI suggests a potential pullback is imminent, but the overall trend remains bullish due to the price being above key moving averages. Trade Plan: - Suggested Entry: $26.50 (considering a slight pullback) - Stop Loss: $25.00 (to limit downside risk) - Take Profit Targets: - Target 1: $28.00 (approx. 5.2% ROI) - Target 2: $29.50 (approx. 10.0% ROI) - Target 3: $31.50 (approx. 17.0% ROI) This trade plan allows for a conservative entry while targeting significant upside potential. Monitor RSI for reversals and adjust stop loss accordingly. https://privateprofiteers.com
0 · Reply
FALCON765
FALCON765 Dec. 24 at 4:31 PM
$IMVT BEST IN CLASS !
0 · Reply
FALCON765
FALCON765 Dec. 24 at 4:28 PM
0 · Reply
Sowa5000
Sowa5000 Dec. 24 at 1:16 AM
$IMVT and $VRDN will make some noise at JP Morgan.
0 · Reply
Quantumup
Quantumup Dec. 23 at 2:43 PM
Truist reiterated $VRDN Buy-$41, and said: 'Veli's Priority Review & June 30 PDUFA Set, Confirming Clean, Catalyst-Rich 2026 Set-Up' $AMGN $IMVT NVS ARGX Truist added: This morning's BLA acceptance and priority review for Veli' comes in as expected, though reinforcing of the solid and still-underappreciated execution and opportunity available for VRDN and shares give the clean and attractive set-up across the portfolio; a June 30 PDUFA with robust launch preparations underway open the door to a mid-2026 launch - our base case - and VRDN's foray into TED. On the path for pivotal SC data in early 2026, a mid-year IV PDUFA, and potential launch later this year, we like the multi-pronged but direct-course appreciation potential on VRDN shares and reiterate our Buy rating and $41 price target.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 5:17 PM
Actionable Trade Alert for $IMVT: Market Context: $IMVT is currently trading at $26.18, showing strength with an RSI of 60.47, indicating bullish momentum but not overbought. The stock is above its 30-day moving average (MA30) of $23.82 and significantly above the 50-day moving average (MA50) of $22.36, suggesting a positive trend. Directional Bias: The current price is near the 60-day high of $27.69, providing a potential resistance level. Given the bullish indicators from the RSI and MAs, we anticipate upward movement. Trade Plan: - Suggested Entry: $26.20 - Stop Loss: $24.50 (1.7% below entry) - Take Profit Targets: - Target 1: $27.00 (3.1% ROI) - Target 2: $28.00 (6.9% ROI) - Target 3: $30.70 (17.6% ROI) The targets are set based on resistance levels and potential price action. Monitor closely for any changes in momentum. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
OptionRunners
OptionRunners Dec. 18 at 8:39 PM
$IMVT buyer of the July 17th 2026 $30 calls 1,000 times for $3.72-$4.60
0 · Reply
WallStJesus
WallStJesus Dec. 18 at 8:35 PM
$IMVT JULY BULL SWEEPER
0 · Reply
FALCON765
FALCON765 Dec. 18 at 12:40 PM
$IMVT INSIDER BUYING 350 Million !💥 WHAT HE KNOW.....?!
0 · Reply
RonIsWrong
RonIsWrong Dec. 17 at 5:36 PM
$IMVT quitely
0 · Reply
Latest News on IMVT
Immunovant, Inc. (IMVT) Q2 2026 Earnings Call Transcript

Nov 10, 2025, 12:31 PM EST - 6 weeks ago

Immunovant, Inc. (IMVT) Q2 2026 Earnings Call Transcript


Top 2 Health Care Stocks That May Collapse This Quarter

Sep 9, 2024, 9:12 AM EDT - 1 year ago

Top 2 Health Care Stocks That May Collapse This Quarter

TERN


Immunovant Awarded U.S. Patent for IMVT-1402

Mar 12, 2024, 7:30 AM EDT - 1 year ago

Immunovant Awarded U.S. Patent for IMVT-1402


Best Small-Cap Stocks to Buy for 2024 and Beyond

Dec 14, 2023, 1:24 PM EST - 2 years ago

Best Small-Cap Stocks to Buy for 2024 and Beyond

ARVN ASO BOOT FLYW GH PRVA RCKT


Immunovant to Present at Upcoming Investor Conferences

Nov 13, 2023, 8:00 AM EST - 2 years ago

Immunovant to Present at Upcoming Investor Conferences


Immunovant Could Be Poised For A Breakout In H2 2023

May 24, 2023, 1:14 PM EDT - 2 years ago

Immunovant Could Be Poised For A Breakout In H2 2023


PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 25 at 3:21 PM
Actionable Trade Alert for $IMVT: Market Context: $IMVT is currently trading at $26.88, showing strong momentum with an RSI of 72.23, indicating overbought conditions. The stock is above its 30-day MA of 24.31 and 50-day MA of 23.13, suggesting bullish sentiment. The 60-day high of $27.69 indicates potential resistance, while the low of $15.95 provides a solid support level. Directional Bias: The strong RSI suggests a potential pullback is imminent, but the overall trend remains bullish due to the price being above key moving averages. Trade Plan: - Suggested Entry: $26.50 (considering a slight pullback) - Stop Loss: $25.00 (to limit downside risk) - Take Profit Targets: - Target 1: $28.00 (approx. 5.2% ROI) - Target 2: $29.50 (approx. 10.0% ROI) - Target 3: $31.50 (approx. 17.0% ROI) This trade plan allows for a conservative entry while targeting significant upside potential. Monitor RSI for reversals and adjust stop loss accordingly. https://privateprofiteers.com
0 · Reply
FALCON765
FALCON765 Dec. 24 at 4:31 PM
$IMVT BEST IN CLASS !
0 · Reply
FALCON765
FALCON765 Dec. 24 at 4:28 PM
0 · Reply
Sowa5000
Sowa5000 Dec. 24 at 1:16 AM
$IMVT and $VRDN will make some noise at JP Morgan.
0 · Reply
Quantumup
Quantumup Dec. 23 at 2:43 PM
Truist reiterated $VRDN Buy-$41, and said: 'Veli's Priority Review & June 30 PDUFA Set, Confirming Clean, Catalyst-Rich 2026 Set-Up' $AMGN $IMVT NVS ARGX Truist added: This morning's BLA acceptance and priority review for Veli' comes in as expected, though reinforcing of the solid and still-underappreciated execution and opportunity available for VRDN and shares give the clean and attractive set-up across the portfolio; a June 30 PDUFA with robust launch preparations underway open the door to a mid-2026 launch - our base case - and VRDN's foray into TED. On the path for pivotal SC data in early 2026, a mid-year IV PDUFA, and potential launch later this year, we like the multi-pronged but direct-course appreciation potential on VRDN shares and reiterate our Buy rating and $41 price target.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 5:17 PM
Actionable Trade Alert for $IMVT: Market Context: $IMVT is currently trading at $26.18, showing strength with an RSI of 60.47, indicating bullish momentum but not overbought. The stock is above its 30-day moving average (MA30) of $23.82 and significantly above the 50-day moving average (MA50) of $22.36, suggesting a positive trend. Directional Bias: The current price is near the 60-day high of $27.69, providing a potential resistance level. Given the bullish indicators from the RSI and MAs, we anticipate upward movement. Trade Plan: - Suggested Entry: $26.20 - Stop Loss: $24.50 (1.7% below entry) - Take Profit Targets: - Target 1: $27.00 (3.1% ROI) - Target 2: $28.00 (6.9% ROI) - Target 3: $30.70 (17.6% ROI) The targets are set based on resistance levels and potential price action. Monitor closely for any changes in momentum. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
OptionRunners
OptionRunners Dec. 18 at 8:39 PM
$IMVT buyer of the July 17th 2026 $30 calls 1,000 times for $3.72-$4.60
0 · Reply
WallStJesus
WallStJesus Dec. 18 at 8:35 PM
$IMVT JULY BULL SWEEPER
0 · Reply
FALCON765
FALCON765 Dec. 18 at 12:40 PM
$IMVT INSIDER BUYING 350 Million !💥 WHAT HE KNOW.....?!
0 · Reply
RonIsWrong
RonIsWrong Dec. 17 at 5:36 PM
$IMVT quitely
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 4:02 AM
Actionable Trade Alert for $IMVT: Market Context: $IMVT is currently trading at $26.61, with a strong RSI of 64.43, indicating bullish momentum. The stock is above both the 30-day MA (23.64) and the 50-day MA (21.94), reinforcing a positive trend. The recent high of $27.29 suggests potential resistance, while the low of $14.86 provides a solid support level. Directional Bias: Given the strong RSI and the stock's position above key moving averages, the bias is bullish. The stock is trending upward, and the proximity to the 60D high indicates potential for further gains. Trade Plan: - Suggested Entry: $26.70 (slightly above the last close) - Stop Loss: $25.00 (to limit downside risk) - Take Profit Targets: 1. $27.00 (1.12% gain) 2. $28.00 (4.83% gain) 3. $31.25 (17.5% gain) With these targets, the trade offers a risk-reward ratio that aligns with the desired 17% ROI on the third target. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
erevnon
erevnon Dec. 15 at 6:33 PM
Goldman Sachs maintains Immunovant $IMVT at Neutral and raises the price target from $18 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
JarvisFlow
JarvisFlow Dec. 15 at 5:49 PM
Goldman Sachs has adjusted their stance on Immunovant ( $IMVT ), setting the rating to Neutral with a target price of 18 → 28.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 7:36 AM
Actionable Trade Alert for $IMVT: Market Context: $IMVT is currently trading at $26.42, showing strong momentum as indicated by an RSI of 70.05, suggesting it is overbought. However, the price is near its 60D high of $27.06, indicating potential resistance. Directional Bias: The bullish sentiment is supported by the 30-day moving average (MA30) at $23.5 and the 50-day moving average (MA50) at $21.56, both below the current price, indicating upward momentum. The high-low range shows significant volatility, with a 60D low of $14.58. Trade Plan: - Suggested Entry: $26.50 - Stop Loss: $25.00 (1.5 ATR below entry) - Take Profit Targets: 1. $27.00 (1.89% ROI) 2. $28.00 (5.66% ROI) 3. $30.00 (13.67% ROI) Target 3 offers a potential ROI of 13.67%, close to the desired 17%. Monitor price action closely for adjustments. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
GSP
GSP Dec. 14 at 5:07 PM
0 · Reply
RonIsWrong
RonIsWrong Dec. 12 at 10:44 PM
$IMVT $550 million offering closed today. ROIV bought $350M of it, apparently
0 · Reply
itsphd
itsphd Dec. 12 at 7:34 AM
$IMVT Interesting need to look more into this
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 12 at 12:29 AM
Actionable Trade Alert for $IMVT: Market Context: $IMVT is currently trading at $25.33, with a strong bullish sentiment indicated by an RSI of 64.69, suggesting it is nearing overbought territory but still has room to move higher. The stock is above its 30-day moving average (MA30) of $23.47 and 50-day moving average (MA50) of $21.37, indicating a positive trend. Directional Bias: The recent price action is in a bullish phase, supported by the proximity to the 60-day high of $27.06, which serves as a potential resistance level. The ATR of 1.19 suggests moderate volatility, allowing for reasonable price movement. Trade Plan: - Suggested Entry: $25.50 - Stop Loss: $24.00 (approximately 5.9% risk) - Take Profit Targets: 1. $26.50 (4.0% gain) 2. $27.00 (5.3% gain) 3. $29.65 (17.4% gain) This plan offers a favorable risk-reward ratio with a potential 17% ROI on the third target. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
Godwins26
Godwins26 Dec. 11 at 4:53 PM
3rd Watchlist today 😊 $ATPC $AFJK $IMVT $VOR $IDR
0 · Reply
Pika_Capital
Pika_Capital Dec. 11 at 4:52 PM
$IMVT works like a charm. Retail is always scared to buy a big dip.
0 · Reply
Tdorsey1776
Tdorsey1776 Dec. 11 at 4:43 PM
$IMVT Leerink sole deal runner....someone wanted to write a huge check to get long.
0 · Reply
Tdorsey1776
Tdorsey1776 Dec. 11 at 4:40 PM
$IMVT Almost every decent size Bio raise is being bought. Adding on dips.....GLTA
0 · Reply